G
Giulia Perrone
Researcher at Harvard University
Publications - 20
Citations - 1395
Giulia Perrone is an academic researcher from Harvard University. The author has contributed to research in topics: In vivo & Bone marrow. The author has an hindex of 11, co-authored 20 publications receiving 1286 citations.
Papers
More filters
Journal ArticleDOI
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
Gullu Gorgun,Elisabetta Calabrese,Teru Hideshima,Jeffrey Ecsedy,Giulia Perrone,Mala Mani,Hiroshi Ikeda,Giada Bianchi,Yiguo Hu,Diana Cirstea,Loredana Santo,Yu-Tzu Tai,Sabikun Nahar,Mei Zheng,Madhavi Bandi,Ruben D. Carrasco,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +20 more
TL;DR: The preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM, and combined with dexamethasone, doxorubicin, or bortezomib induces synergistic/additive anti-MM activity in vitro.
Journal ArticleDOI
Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
Gullu Gorgun,Elisabetta Calabrese,Ender Soydan,Teru Hideshima,Giulia Perrone,Madhavi Bandi,Diana Cirstea,Loredana Santo,Yiguo Hu,Yu-Tzu Tai,Sabikun Nahar,Naoya Mimura,Claire Fabre,Noopur Raje,Nikhil C. Munshi,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +17 more
TL;DR: It is demonstrated that modulation of SOCS1 may enhance immune response and efficacy of IMiDs in MM and the mechanism of inhibitory-cytokine signaling in effector cells and MM cells is defined.
Journal ArticleDOI
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Giulia Perrone,Naoya Miura,Hiroshi Yasui,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Loredana Santo,Sonia Vallet,Diana Cristea,Elisabetta Calabrese,Gullu Gorgun,Noopur Raje,Paul G. Richardson,Nikhil C. Munshi,Nikhil C. Munshi,Brian J. Lannutti,Kamal D. Puri,Neill A. Giese,Kenneth C. Anderson +21 more
TL;DR: The studies show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM.
Journal ArticleDOI
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Hiroshi Ikeda,Teru Hideshima,Mariateresa Fulciniti,Robert J. Lutz,Hiroshi Yasui,Yutaka Okawa,Tanyel Kiziltepe,Sonia Vallet,Samantha Pozzi,Loredana Santo,Giulia Perrone,Yu-Tzu Tai,Diana Cirstea,Noopur Raje,Christoph Uherek,Benjamin Dälken,Silke Aigner,Frank Osterroth,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson +20 more
TL;DR: The results provide the preclinical framework supporting evaluation of nBT062-maytansinoid derivatives in clinical trials to improve patient outcome in MM.
Journal ArticleDOI
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea,Teru Hideshima,Scott J. Rodig,Loredana Santo,Samantha Pozzi,Sonia Vallet,Hiroshi Ikeda,Giulia Perrone,Gullu Gorgun,Kishan Patel,Neil P. Desai,Peter Sportelli,Shweta Kapoor,Shireen Vali,Siddhartha Mukherjee,Nikhil C. Munshi,Kenneth C. Anderson,Noopur Raje +17 more
TL;DR: It is suggested that mutual suppression of the PI3K/Akt/mTOR pathway by rapamycin and perifosine combination induces synergistic MM cell cytotoxicity, providing the rationale for clinical trials in patients with relapsed/refractory MM.